Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials

Edward J Gane; Stephen Pianko; Stuart K Roberts; Alexander J Thompson; Stefan Zeuzem; Eli Zuckerman; Ziv Ben-Ari; Graham R Foster; Kosh Agarwal; Alex L Laursen; Jan Gerstoft; Wei Gao; Hsueh-Cheng Huang; Brian Fitzgerald; Doreen Fernsler; Jerry J Li; Anjana Grandhi; Hong Liu; Feng-Hsiu Su; Shuyan Wan; Zhen Zeng; Huei-Ling Chen; Frank J Dutko; Bach-Yen T Nguyen; Janice Wahl; Michael N Robertson; Eliav Barr; Wendy W Yeh; Rebeca M Plank; Joan R Butterton; Rafael Esteban

Journal article

Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials

Edward J Gane, Stephen Pianko, Stuart K Roberts, Alexander J Thompson, Stefan Zeuzem, Eli Zuckerman, Ziv Ben-Ari, Graham R Foster, Kosh Agarwal, Alex L Laursen, Jan Gerstoft, Wei Gao, Hsueh-Cheng Huang, Brian Fitzgerald, Doreen Fernsler, Jerry J Li, Anjana Grandhi, Hong Liu, Feng-Hsiu Su, Shuyan Wan Show all

The Lancet Gastroenterology & Hepatology | ELSEVIER INC | Published : 2017

DOI: 10.1016/S2468-1253(17)30159-0